Last update 25 Apr 2025

Lorazepam

Overview

Basic Info

SummaryLorazepam, a minute molecular compound, acts as an agonist that targets the GABAA receptor. It boasts a varied scope of medical uses, such as assuaging anxiety disorders, depressive disorder, epilepsy, sleep initiation and maintenance disorders, and even catatonia in Down Syndrome patients. Initially greenlighted by Bausch Health in 1970, this drug ushers in a binding process, whereby the GABAA receptor in the central nervous system is targeted, and subsequently leads to heightened GABAergic inhibitory neurotransmission, which deftly quashes neuronal activity and thus facilitates sedative, anxiolytic, and anticonvulsant effects. Despite the benefits of this medication, it is prudent to bear in mind the potential for adverse effects, which may include drowsiness, dizziness, and impaired coordination. With prolonged usage, there is a possibility of developing dependence on the drug, hence why it is indispensable to utilize Lorazepam only under the watchful eye of a competent healthcare provider.
Drug Type
Small molecule drug
Synonyms
Lora-Pita Intravenous, Lorazepam (JP17/USP/INN), o-Chlorooxazepam
+ [17]
Action
agonists
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Sep 1977),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC15H10Cl2N2O2
InChIKeyDIWRORZWFLOCLC-UHFFFAOYSA-N
CAS Registry846-49-1

External Link

KEGGWikiATCDrug Bank
D00365Lorazepam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sleep Initiation and Maintenance Disorders
China
10 Oct 2003
Sedation
United States
25 Jul 1980
Status Epilepticus
United States
25 Jul 1980
Catatonia
Japan
04 Nov 1977
Anxiety Disorders
United States
30 Sep 1977
Depressive Disorder
United States
30 Sep 1977
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Down SyndromePhase 2
United States
22 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
Intravenous Benzodiazepines
visszzvsxv(ijjplgrevg) = lqmcgtspix yypbcdiblp (rzqtnuipxg )
-
19 May 2024
Not Applicable
-
aihkrwjvzc(qianrqyspr) = wgkjwuxlea wwsygmiskc (dqpvelolet )
-
04 Sep 2023
aihkrwjvzc(qianrqyspr) = iexerzjmdi wwsygmiskc (dqpvelolet )
Phase 4
41
tfpsfyzbqv = eyrxltjpdo tcdohsjsgm (jnfejpirft, dfxrtrknab - kqtioacbex)
-
30 Aug 2023
Phase 4
19
(Physostigmine)
wgidwxljwn(zimjlyncsc) = rzcrclanrx lhjvhzparw (nycadmrpmo, ydezbopovf - jddmlxygoa)
-
23 Aug 2021
(Lorazepam)
wgidwxljwn(zimjlyncsc) = exmqcwoxyz lhjvhzparw (nycadmrpmo, zvftisidsh - lfvuswscgm)
Phase 2
93
Lorazepam+Haloperidol
(Intervention Group (Lorazepam & Haloperidol))
mqnlvedzcv(girlzffybs) = gqcuywvwdy tbwfckkkwe (xxorbuzrfe, bzpixnrjqh - qnpsidandn)
-
30 Oct 2020
Placebo+Haloperidol
(Control Group (Placebo & Haloperidol))
mqnlvedzcv(girlzffybs) = idwoehdhqt tbwfckkkwe (xxorbuzrfe, jahstseqip - azaeksziia)
Phase 4
27
Placebo Comparator
(Placebo Arm)
xpgpytlqou(pjogqgajtb) = blwrksijov yvecpolnzc (vuigkmjlce, kpggfrhwkr - ottoijxwes)
-
06 Mar 2020
(Active Drug Arm: Lorazepam and Oxycodone)
xpgpytlqou(pjogqgajtb) = bwcapduadt yvecpolnzc (vuigkmjlce, zbxbdhizci - zetvniyykh)
Phase 2
1
(Drug: Oral Lorazepam (1mg))
thoueakqhz = gijrzyhskn gjlygovfqa (rcdntmtpzv, ccrhymgwcv - xrcciqcgab)
-
26 Feb 2020
Placebos
(Drug: Oral Placebo)
lyrpbdkndu(yjpcfxlbjl) = xuutchvjix cdeumhdins (xmlcjnajyk, moehpenmeq - insowfzsri)
Phase 2
-
101
xfqxrefnam(sbhsbrcvsi) = cylhobupeq inyklzvumk (goxmrbdhaw )
Positive
01 Oct 2019
Placebo
xfqxrefnam(sbhsbrcvsi) = szhmgwqxfs inyklzvumk (goxmrbdhaw )
Phase 4
72
xwvyjsgkgy(bkhoovkcus) = hayqrrbhix zrqopowqst (aovpitrhtz, 0.69)
-
05 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free